arrow
Y

Yoshihiro Tsukamoto

kobe city medical center general hospital
H指数:17
被引数:929

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Treatment initiation by positive liquid biopsy alone in primary central nervous system lymphoma: A retrospective analysis of a multi-institutional study

仅通过阳性液体活检启动原发性中枢神经系统淋巴瘤的治疗:一项多机构研究的回顾性分析

2026-01-010
PRE
A multi-center retrospective study on lower grade gliomas in Japan

日本多中心回顾性研究:关于低级别胶质瘤

2025-11-010
OAAI
Rapidly progressive scalp and lung metastases with fatal pneumothorax in glioblastoma, IDH-wildtype, with MET and CDK6 amplifications: a case report of clinical course and postmortem autopsy, including genetic analysis

快速进展的头皮和肺部转移伴致命性气胸的IDH-wildtype胶质母细胞瘤(伴有MET和CDK6扩增):一例临床病程及死后尸检的病例报告,包括遗传学分析

2025-05-200
PRE
Near-Infrared Photoimmunotherapy in Brain Tumors-An Unexplored Frontier

近红外光免疫疗法在脑肿瘤中的应用——一个尚未探索的前沿

2025-05-190
OA
Epigenetic upregulation of Schlafen11 renders WNT- and SHH-activated medulloblastomas sensitive to cisplatin
2022-10-236
OA
Detection of 2-Hydroxyglutarate by 3.0-Tesla Magnetic Resonance Spectroscopy in Gliomas with Rare IDH Mutations: Making Sense of False-Positive Cases

通过3.0-特斯拉磁共振波谱在具有罕见IDH突变的神经胶质瘤中检测2-羟基戊二酸: 假阳性病例的意义

2021-11-164
OAAI
GLI3 Is Associated With Neuronal Differentiation in SHH-Activated and WNT-Activated Medulloblastoma
2021-01-185
OAAI
Dramatic response of BRAF V600E-mutant epithelioid glioblastoma to combination therapy with BRAF and MEK inhibitor: establishment and xenograft of a cell line to predict clinical efficacy

BRAF V600E-mutant上皮样胶质母细胞瘤对BRAF和MEK抑制剂联合治疗的显著反应: 预测临床疗效的细胞系的建立和异种移植

2019-07-2546
OAAI